Forest plot illustrating risk ratio of stent thrombosis

Slides:

Advertisements

Similar presentations

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Advertisements

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Volume 149, Issue 6, Pages (June 2016)

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.

Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy.

by Kueiyu Joshua Lin, Daniel E. Singer, Robert J

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Nat. Rev. Cardiol. doi: /nrcardio

Volume 15, Issue 1, Pages (January 2018)

FAERS death cases (all years) for NOACs versus warfarin.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Coronary revascularisation rate (total 5

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Tornado diagram of one-way deterministic sensitivity analysis.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

(A) Illustration of the receiver operating characteristic (ROC) curve (discrimination) of the recalibrated model on the external validation set data. (A)

Figure 9 Management of atrial fibrillation

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Receiver operating characteristics curve of N-terminal pro-atrial natriuretic peptide plasma levels (dark line) and brain natriuretic peptide (dashed line)

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Inflammatory response and CD34+CD45− cell release following percutaneous coronary intervention (PCI). Inflammatory response and CD34+CD45− cell release.

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Comparison of the change in index of microcirculatory resistance (IMR) at each stage of the primary percutaneous coronary intervention (PPCI) for balloon.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Zachary L. Steinberg et al. JACC 2017;69:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Forest plot of the association between early coronary angiography and survival in patients with out-of-hospital cardiac arrest A: including unadjusted.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Gianluigi Savarese et al. JCHF 2016;4:

Forest plot illustrating the risk ratio of major bleeding

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

LAA sizing by different imaging modalities.

Left atrial appendage flow during atrial fibrillation, as determined by pulsed Doppler during transoesophageal echocardiography. Left atrial appendage.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Temporal trends of AF hospitalisation per 100 patients with AF according to main hospitalisation causes between 2006 and *P value for increase trends

Forest plot illustrating the risk ratio of myocardial infarction

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Forest plot illustrating risk ratio of stent thrombosis Forest plot illustrating risk ratio of stent thrombosis. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI, percutaneous coronary interventions; VKAs, vitamin K antagonists. Forest plot illustrating risk ratio of stent thrombosis. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI, percutaneous coronary interventions; VKAs, vitamin K antagonists. Natale Daniele Brunetti et al. Open Heart 2018;5:e000785 ©2018 by British Cardiovascular Society